FDA Issues Warning Regarding the Use of Balloon Angioplasty For Treatment Of Autonomic Dysfunction Disorders
US Food and Drug Administration (FDA) has warned both patients and doctors alike about the use of balloon angioplasty...
Merkel Cell Carcinoma (MCC) gets it first line of treatment approved by the FDA
Skin cancer is common; however, Merkel cell carcinoma (MCC) is a rare type of aggressive skin cancer that affects...
FDA gives a green signal for maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with Niraparib
Adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who have responded completely or partially to...
FDA Approves First New Treatment For Frequent Urination In Night
Noctiva a nasal spray for adults with nocturnal polyuria has been approved by the US Food and Drug Administration....
New Antibiotic Management For Lower Respiratory Tract Infections And Sepsis Cleared By FDA
FDA has given a green signal for the expanded use of a procalcitonin test to help determine the use...
FDA approves Odactra for house dust mite allergies
A team of officials with the FDA have recently approved Merck, Sharp & Dohme Corporation’s Odactra one of the...
Say Hello To The World’s Tiniest Pacemaker
Since the introduction of pacemakers in the 1950s till date, technology has advanced so much that the first ones...
New exercise guidelines for type 1 diabetes patients
Major obstacles in blood sugar management for people with type 1 diabetes include hypoglycaemia, loss of glycaemic control, and...
Olaratumab – FDA approved first line agent for the treatment of soft tissue sarcoma
Soft-tissue sarcomas (STS) are an uncommon and diverse group of malignancies originating from mesenchymal precursors that are responsible for...
Pimavanserin – Breakthrough therapy for psychoses associated with Parkinson’s disease
Parkinson’s disease (PD) is a debilitating neurodegenerative disorder associated with both motor as well as non-motor symptoms (NMS). Though...